Evidence map›Paper›PMID 41324068›Full record

ArticleBladder (San Francisco, Calif.)2025

Real-world management of T1 high-grade bladder cancer: A 14-year retrospective single-center study.

Zexuan Lv, Yi Feng, Bingyang Guo, Bin Jiang, Hongyu Zhang, Yin Lu, Wenfeng Gao, Jinlu Tang, Qing Ai, Qiang Cheng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zexuan LvDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Yi FengDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Bingyang GuoDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Bin JiangDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Hongyu ZhangDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Yin LuDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Wenfeng GaoDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Jinlu TangDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Qing AiDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
Qiang ChengDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.
HongZhao LiDepartment of Urology, The Third Medical Center, People's Liberation Army General Hospital, Beijing 100039, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: T1 high-grade (T1HG) bladder cancer (BC) carries substantial risks of recurrence and progression, deserving of heightened clinical attention. Objective: The present study evaluated the management approaches and reported 14-year real-world outcomes in patients with T1HG BC from a single-center cohort. Methods: Data were retrospectively collected from primary T1HG patients who had undergone transurethral resection of bladder tumors (TURBT) at our institution between 2010 and 2023. A total of 165 patients were included. Their baseline characteristics, pathological findings, adjuvant therapies, recurrence, progression, and survival outcomes were analyzed. Predictors of tumor recurrence were modeled using multivariable analyses. Results: Tumor recurrence was significantly associated with post-operative Bacillus Calmette-Guérin (BCG) treatment (odds ratio [OR]: 0.315, Conclusion: Recurrence in T1HG disease is associated with BCG therapy and tumor multifocality, with a high BMI potentially promoting relapse.

Indexed as

Bacillus Calmette–Guérin treatmentBladder preservationCystectomyNon-muscle invasive bladder cancerTumor recurrence

Identifiers

PMID41324068
PMCPMC12661534

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.